Plain-English translation of NCT07358611 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a personalized approach to treating persistent atrial fibrillation (an irregular heartbeat condition) using a non-invasive mapping system called SAHRA. Instead of treating the heart the same way for every patient, doctors will use this advanced mapping technology to identify the specific areas in your heart that are causing the irregular rhythm, then perform ablation surgery (controlled burning of heart tissue) on those exact problem spots. The goal is to see if this customized approach works better than the current standard treatment.
Many patients with persistent atrial fibrillation don't get better with standard ablation surgery alone, especially if their heart chambers are enlarged. This trial exists to find out whether targeting the specific abnormal areas that doctors identify using non-invasive mapping technology can improve outcomes for these patients who need a more personalized approach.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will first have non-invasive heart mapping scans performed to identify the abnormal areas in your heart causing the irregular rhythm. Then you will undergo ablation surgery where your doctor will perform the standard treatment (isolating the pulmonary veins) plus targeted ablation of the specific problem areas your mapping identified. Your participation involves the mapping scans and the ablation procedure itself, with follow-up visits to monitor your recovery and check whether your heart rhythm has improved.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
Spain